At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLRN Acelyrin, Inc.
Post-Market Trading 03-24 16:51:17 EDT
2.64
-0.11
-4.00%
盘后2.64
+0.000.00%
16:37 EDT
| High2.78 | Low2.60 | Vol501.03K |
| Open2.78 | D1 Closing2.75 | Amplitude6.55% |
| Mkt Cap265.87M | Tradable Cap191.66M | Total Shares100.71M |
| T/O1.33M | T/O Rate0.69% | Tradable Shares72.60M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones · 10:00
ACELYRIN Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03-20
Insider Stock Sales Shake Up ACELYRIN, INC.
TIPRANKS · 03-20
Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now
Insider Monkey · 03-18
Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
Dow Jones · 03-13
Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell
MT Newswires Live · 03-13
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
THOMSON REUTERS · 03-13
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
GlobeNewswire · 03-13
Sector Update: Health Care Stocks Lower Tuesday Afternoon
MT Newswires Live · 03-04
BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth
Reuters · 03-04
ACELYRIN Shares Down 6.5% After Co Reiterates Merger With Alumis
THOMSON REUTERS · 03-04
Acelyrin Reaffirms Merger Deal With Alumis
MT Newswires Live · 03-04
REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer
Reuters · 03-04
Acelyrin says Concentra indication not expected to result in superior proposal
TIPRANKS · 03-04
BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger
Reuters · 03-04
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger
TIPRANKS · 03-04
BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger
Reuters · 03-04
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
THOMSON REUTERS · 03-04
Press Release: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Dow Jones · 03-04
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
THOMSON REUTERS · 03-04
Introduction
Company Name.
Acelyrin, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
2023-05-05
Main Business:
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Issue price:
18.00
Invest in Global Markets with Tiger Brokers!Open App